Advertisement

The Phase III safety & efficacy study - titled “A 14-Week, Multi-Center Study of [S,S]-Reboxetine in Patients with Fibromyalgia” – is sponsored by Pfizer.

With a target enrollment of some 1,148 subjects, the trial will involve four arms – 3 different doses of reboxetine and placebo (fake) dose.

Reboxetine, which is an antidepressant also used in treatment of ADD/ADHD and panic disorder in Europe but not prescribed in the US, is a norepinephrine reuptake inhibitor (NRI). It acts by blocking the reuptake of the neurotransmitter norepinephrine (maintaining higher levels).

As part of the trial, participants (diagnosed with Fibromyalgia and over age 18) will receive: free study related medication and procedures, physical exams and lab tests, monitoring and evaluation, and financial compensation for participation & travel.

For more information on this study (ClinicalTrials.gov ID number NCT00612170) - and to review the study locations see the ClinicalTrials.gov listing at http://www.clinicaltrials.gov/ct2/show/NCT00612170

Important Contact Information: Enquiries about the 124 study locations are being routed through a central 800 number. To get contact information for the study location nearest you, use the Pfizer ClinicalTrials.gov Call Center for the study (1-800-718-1021). The service will ask you to leave a message with:

The service promises to get back to you "within 2 business days."

___
This information has not been evaluated by the FDA. It is not meant to prevent, diagnose, treat or cure any illness, condition, or disease. It is very important that you make no change in your healthcare plan or health support regimen without researching and discussing it in collaboration with your professional healthcare team.